| Document |
Document Title |
|
WO/2021/065980A1 |
Provided is a BET degrader. A BET degrader including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 and L2 are the same or different and represent a low molecular ligand f...
|
|
WO/2021/066123A1 |
Provided is a novel metal complex which can be used as an electron transporting material. Metal complexes respectively represented by formulae (1) to (3). RA1 to RA9, RC1 to RC8 and RE1 to RE6 independently represent a single bond, an al...
|
|
WO/2021/063335A1 |
The present application provides a compound represented by formula (I), or isomer or pharmaceutically acceptable salt thereof, and use thereof in the preparation of an ERK1/2-mediated disease drug.
|
|
WO/2021/065374A1 |
The present invention improves heat resistance. A photoelectric conversion element 10 which includes a positive electrode 12, a negative electrode and an active layer 14 provided between said positive and negative electrodes, wherein t...
|
|
WO/2021/067606A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...
|
|
WO/2021/067217A1 |
The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.
|
|
WO/2021/060453A1 |
The present invention pertains to a compound represented by formula (1a) [in the formula: p represents 1 or 2; R1 to R4 represent a hydrogen atom, etc.; ring A represents a cycloalkylene, etc.; L represents a single bond, etc.; and R rep...
|
|
WO/2021/060042A1 |
The purpose of the present invention is to provide: a compound that, when being formed into a film, provides excellent reproducibility of carrier mobility regardless of the film-forming method; a composition containing the compound; a fi...
|
|
WO/2021/057963A1 |
Provided are an RET inhibitor, a pharmaceutical composition comprising same and a use thereof. Specifically, the present invention relates to a compound as shown in formula (I) or a stereoisomer, geometrical isomer, tautomer, nitrogen ox...
|
|
WO/2021/062238A1 |
This disclosure relates to methods and compositions for treating sickle cell anemia or thalassemia in a subject in need thereof. As described herein in a first aspect the present disclosure provides a method of treating an inherited bloo...
|
|
WO/2021/055538A1 |
Provided herein are compounds and pharmaceutical compositions comprising a therapeutically effective amount of such compounds, or pharmaceutically acceptable salts, and a pharmaceutically acceptable excipient, and methods of treating neu...
|
|
WO/2021/051899A1 |
The present invention provides a cyano-substituted cyclic hydrazine derivative, comprising: a compound represented by the following structural formula or a stereoisomer, a geometric isomer, a tautomer, a racemate, a hydrate, a solvate, a...
|
|
WO/2021/055589A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
|
|
WO/2021/032004A9 |
Disclosed in the present invention are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present invention also provides a method for preparing said compound, a composition containing said ...
|
|
WO/2021/053046A1 |
The present invention relates to compounds of formula (I), to processes for preparing the compounds, and to electronic devices containing one or more of the compounds.
|
|
WO/2021/050059A1 |
The present disclosure relates to DNA-PK inhibiting compounds and prodrugs thereof that are useful in the treatment of diseases, including cancer. In particular, the compounds sensitise cancers to therapies such as chemotherapy and radio...
|
|
WO/2021/047547A1 |
The present invention provides a novel tricyclic aromatic heterocyclic compound, a preparation method therefor, a pharmaceutical composition and an application thereof. Specifically, the present invention provides a compound as represent...
|
|
WO/2021/047556A1 |
Provided are a nitrogen-containing heterocyclic compound, and a preparation method therefor, a pharmaceutical composition comprising same and the use thereof. Specifically, provided in the present invention is a compound as shown in form...
|
|
WO/2021/047584A1 |
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2021/047555A1 |
Provided are the preparation of an aromatic heterocyclic derivative as an immunomodulator and an application thereof. Specifically, provided is a compound represented by formula I below, or an optical isomer, hydrate, solvate, or pharmac...
|
|
WO/2021/043850A1 |
The present invention relates to compounds of formula (1) or (2), wherein R1 and R3 are purine or a purine analog and R2 and R4 are a small functional group. The invention also relates to intermediates of the synthesis of compounds of fo...
|
|
WO/2021/042890A1 |
A heterocyclic compound shown in formula I and application thereof as a Trk kinase inhibitor.
|
|
WO/2021/041861A1 |
Provided herein are N-(2-aminophenyl)-prop-2-enamide derivatives, such as those of Formula (I), methods for the synthesis thereof, and uses thereof in the treatment of cancer, such as SALL4-expressing cancer, in a cell or subject in need...
|
|
WO/2021/039961A1 |
Provided are a ring-fused pyrazole derivative, which is useful as a therapeutic agent and/or a preventive agent for diseases associated with Nav1. 1 and various central nervous system diseases, and/or a pharmaceutically acceptable salt t...
|
|
WO/2021/032323A1 |
The present invention discloses compounds according to Formula I, wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmace...
|
|
WO/2021/028382A1 |
The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful f...
|
|
WO/2021/027943A1 |
A pyrimidinopyridazinone derivative and a medical use thereof. The derivative has a structure represented by general formula (I). The present invention also relates to a preparation method for the compound of general formula (I), a pharm...
|
|
WO/2021/030142A1 |
The present disclosure relates generally to compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatmen...
|
|
WO/2021/027172A1 |
Disclosed is a hole transport material with a structural general formula of (A), wherein group R is any one of a carbazole group and a derivative group thereof, a diphenylamine group and a derivative group thereof, a phenoxazine group an...
|
|
WO/2021/028854A1 |
The present invention provides a compound of Formula (I): (I) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides p...
|
|
WO/2021/027911A1 |
The present invention relates to a spirocyclic compound and a preparation method therefor and use thereof, in particular to a compound represented by formula (1) and a preparation method therefor, and use of the compound of formula (1) a...
|
|
WO/2021/023209A1 |
The present invention relates to the field of medicinal chemistry, and relates in particular to nitrogen-containing polycyclic fused ring compounds represented by formula I, and a pharmaceutical composition thereof, a preparation method ...
|
|
WO/2021/024039A1 |
Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treat...
|
|
WO/2021/023204A1 |
Disclosed is a use of a CDK4/6 inhibitor in combination with a multi-target tyrosine kinase inhibitor in preparing a medicament for treating a tumor. Specifically, the CDK4/6 inhibitor is a compound represented by formula (I) or a pharma...
|
|
WO/2021/018287A1 |
Provided is a compound with inhibitory activity on SHP2, a preparation method therefor, and a use thereof. Specifically, provided is a compound represented by formula (I), a pharmaceutically acceptable salt thereof, a solvate, an isotopi...
|
|
WO/2021/017069A1 |
Disclosed are a pyrrolopyrazole derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a class of pyrrolopyrazole derivatives represented by general formula (I), ...
|
|
WO/2021/017114A1 |
A cyclic compound and a use thereof, and an electronic device. The cyclic compound comprises at least compounds represented by formulas 001-011, the cyclic compound has good thermal stability and has a matching LUMO energy level to an ad...
|
|
WO/2021/020363A1 |
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...
|
|
WO/2021/021775A1 |
The present disclosure encompasses solid state forms of Risdiplam, including crystalline polymorphs of Risdiplam, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2021/014365A1 |
Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicam...
|
|
WO/2021/011913A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand whi...
|
|
WO/2021/008455A1 |
Provided are an RET selective inhibitor, a preparation method therefor and a use thereof. Provided are a compound of formula (I) and a pharmaceutically acceptable salt, a solvent, a polymorph or an isomer thereof, a pharmaceutical compos...
|
|
WO/2021/007882A1 |
The present invention relates to an organic compound of a nitrogen-containing heterocycle, and an organic electroluminescent device. The structural general formula of the organic compound of the nitrogen-containing heterocycle is shown i...
|
|
WO/2021/009212A1 |
The invention relates to compounds of Formula I which are useful as antibacterial agents in medicine.
|
|
WO/2021/009365A1 |
A compound of formula (I): wherein: Y is (CH2)n, where n is from 2 to 4; W1 and W11 are independently selected from OH and ORP, where RP is Me or Et.
|
|
WO/2021/007269A1 |
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer, Formula (I).
|
|
WO/2021/005034A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein R1, R2, X, and Y are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...
|
|
WO/2021/003157A1 |
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X...
|
|
WO/2021/001330A1 |
The application relates to heterocyclic compounds of the general formula (I), a process for their preparation, pharmaceutical compositions containing them and their medical use. The compounds act as inhibitors of monoacylglycerol lipase ...
|
|
WO/2021/001739A1 |
The present disclosure relates to novel translational enhancers comprising an eukaryotic initiation factor 4E (eIF4E) ligand attached to a dinucleotide. The present disclosure also relates to RNA molecules (e.g., mRNAs) comprising the no...
|
